Ieq Capital LLC Raises Position in DexCom, Inc. (NASDAQ:DXCM)

Ieq Capital LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 3.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,749 shares of the medical device company’s stock after purchasing an additional 730 shares during the period. Ieq Capital LLC’s holdings in DexCom were worth $2,353,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Bank of New Hampshire purchased a new position in DexCom during the 1st quarter valued at about $1,508,000. Eagle Asset Management Inc. increased its holdings in DexCom by 21.5% during the 4th quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock worth $217,929,000 after acquiring an additional 310,728 shares during the period. Alberta Investment Management Corp lifted its stake in DexCom by 27.0% in the 4th quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock worth $40,123,000 after purchasing an additional 68,723 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the period. Finally, Los Angeles Capital Management LLC grew its position in shares of DexCom by 62.5% during the 1st quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock valued at $49,520,000 after purchasing an additional 137,336 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Activity

In other DexCom news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the sale, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders have sold a total of 2,483 shares of company stock valued at $201,708 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

Shares of DXCM stock opened at $70.43 on Friday. The company has a market capitalization of $28.01 billion, a price-to-earnings ratio of 45.44, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company’s 50-day moving average is $78.19 and its 200 day moving average is $109.54.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.34 earnings per share. Sell-side analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on DXCM shares. Morgan Stanley dropped their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. BTIG Research cut their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. Finally, UBS Group reduced their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.